大葉大學圖書館 |

Inflammatory pathways in diabetes[electronic resource] :biomarkers and clinical correlates /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.462072
書名/作者:	Inflammatory pathways in diabetes : biomarkers and clinical correlates // edited by Michael Pugia.
其他作者:	Pugia, Michael.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	xvi, 219 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Diabetes.
標題:	Inflammation.
標題:	Biochemical markers.
標題:	Biomedicine.
標題:	Immunology.
標題:	Pharmacology/Toxicology.
標題:	Metabolic Diseases.
標題:	Biochemistry, general.
ISBN:	9783319219271
ISBN:	9783319219264
內容註:	Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review)
摘要、提要註:	This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.
電子資源:	http://dx.doi.org/10.1007/978-3-319-21927-1

Inflammatory pathways in diabetes[electronic resource] :biomarkers and clinical correlates /
Inflammatory pathways in diabetesbiomarkers and clinical correlates /[electronic resource] :edited by Michael Pugia. - Cham :Springer International Publishing :2015. - xvi, 219 p. :ill., digital ;24 cm. - Progress in inflammation research. - Progress in inflammation research..

Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review)

This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.

ISBN: 9783319219271

Standard No.: 10.1007/978-3-319-21927-1doiSubjects--Topical Terms:

208538
Diabetes.

LC Class. No.: RC660

Dewey Class. No.: 616.462072

Inflammatory pathways in diabetes[electronic resource] :biomarkers and clinical correlates /
LDR:03401nam a2200325 a 4500 001 443690
003 DE-He213
005 20160411133208.0
006 m d
007 cr nn 008maaau
008 160715s2015 gw s 0 eng d
020 $a 9783319219271 $q (electronic bk.)
020 $a 9783319219264 $q (paper)
024 7 $a 10.1007/978-3-319-21927-1 $2 doi
035 $a 978-3-319-21927-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC660
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.462072 $2 23
090 $a RC660 $b .I43 2015
245 0 0 $a Inflammatory pathways in diabetes $h [electronic resource] : $b biomarkers and clinical correlates / $c edited by Michael Pugia.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a xvi, 219 p. : $b ill., digital ; $c 24 cm.
490 1 $a Progress in inflammation research
505 0 $a Part 1. Introduction -- 1. Impact of inflammation and the innate immunity response in obesity mediated diabetes (lit review) -- Part 2. Impact of complement on diabetic disease -- 2. Complement and Complement Regulatory Proteins in Diabetes -- Part 3. Role of C terminal fragment of adiponectin receptor in inhibition of insulin degradation -- 3. Development of adiponectin receptor C terminal fragment bioassays -- 4. Protease inhibition and biological distribution of the C terminal fragment of adiponectin receptor -- 5. Cell & biological models for the C terminal fragment of adiponectin receptor -- 6. C-Terminal fragment of adiponectin receptor clinical correlations -- Part 4. Uristatin assay for prediction of renal and other clinical events -- 7. Uristatin immunoassay usage in glomerular nephritis assessment -- 8. Acute Response of Uristatin in Surgery -- 9. Cardiovascular and metabolic syndrome impact on uristatin -- 10. Uristatin anti-inflammatory cellular signaling -- Part 5. Summary -- 11. Overview of progress in new markers for diabetes inflammation (Literatue Review)
520 $a This book discusses recent advances in new anti- and pro-inflammatory pathways in diabetic disease, and identifies new diagnostic immunological methods that offer potential companion diagnostics for diabetic diseases. New methods in proteomics, mass spectroscopy, immunological assay design, measurement of cellular signal transduction and protease inhibition are used to clarify new biochemical pathways. Biomarker validation in animal models and correlations in humans for diagnostic clinical trials shed new light on the impact of diabetic diseases. The book reviews current understanding of inflammatory pathways in the pathophysiology of insulin resistance, metabolic syndrome, nephritis and other diabetic inflammatory conditions, and is the first to describe the impact of novel adipokines, protease inhibitors and complement markers. By presenting new methodologies for biomarker discovery, it provides a valuable resource for researchers studying clinical diagnosis, drug development, bio-analytical chemistry, proteomics and biochemistry. It is also useful for those conducting clinical and biological studies for targeted drug development. The methodologies and approaches can be applied to other markers, and the information will be helpful in the preparation of research grant applications.
650 0 $a Diabetes. $3 208538
650 0 $a Inflammation. $3 431284
650 0 $a Biochemical markers. $3 431086
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Immunology. $3 402223
650 2 4 $a Pharmacology/Toxicology. $3 463455
650 2 4 $a Metabolic Diseases. $3 465858
650 2 4 $a Biochemistry, general. $3 463554
700 1 $a Pugia, Michael. $3 634577
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Progress in inflammation research. $3 607363
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-21927-1
950 $a Biomedical and Life Sciences (Springer-11642)